Multi-epitope HER2 peptide vaccine (Mayo Clinic)

N/A

Report date: 2022/03/03 09:37:50

Base Information

Drug NameMulti-epitope HER2 peptide vaccine (Mayo Clinic)
Drug Alias NameH2NVACHER2 Specific Helper T-cell Epitope Vaccine H2NVACHER2 Peptide Vaccine H2NVAC
ClassificationVaccines > Development/production technology > Synthetic peptide vaccineVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsBreast NeoplasmsCarcinoma, Ductal, Breast
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMayo Clinic
China Registration ClassN/A

Develop Information

Active CompaniesMayo Clinic
Inactive CompaniesN/A
Active IndicationsBreast NeoplasmsCarcinoma, Ductal, Breast
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A